Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying pasritamig JNJ-78278343 combined with various other agents to treat metastatic prostate cancer, including both castration-resistant and hormone-sensitive types. This phase 1b trial aims to find the recommended phase 2 dose of pasritamig with these combination treatments and to assess safety at these doses. The study involves sequential dose escalation and expansion phases to evaluate tolerability and adverse effects. Participants receive pasritamig together with one of several combination agents such as cetrelimab, cabazitaxel, docetaxel, apalutamide, enzalutamide, darolutamide, abiraterone acetate plus prednisone, lutetium Lu-177 vipivotide tetraxetan, or JNJ-101556143. In Part 1, the dose of pasritamig is gradually increased to determine the recommended phase 2 regimen. Part 2 involves treating participants at these recommended doses to further monitor safety and response. During the study, participants are closely monitored for dose-limiting toxicities within the first 21 days and adverse events over nearly three years. Researchers will measure overall response, prostate specific antigen levels, radiographic progression-free survival, time to response, and duration of response. The trial includes regular assessments of disease status, safety labs, and physical exams while participants receive treatment and during follow-up, contributing to understanding the combination regimens safety and activity.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of the study drug Seltorexant compared with a placebo in adults and elderly participants with major depressive disorder MDD, a common mood disorder marked by persistent sadness and loss of interest. This Phase 3 study includes a double-blind treatment phase to measure improvement in depressive symptoms specifically in participants with moderate-to-severe insomnia symptoms. The study also aims to assess long-term safety and tolerability of Seltorexant in an open-label treatment phase. During the double-blind phase, participants will take either a Seltorexant tablet or a matching placebo once daily for 42 days. Those who qualify for the open-label phase will continue taking Seltorexant daily for up to 6 months. The study compares the two groups to understand how well Seltorexant works alone in treating MDD. Participants will undergo clinical assessments including depression rating scales, sleep disturbance questionnaires, and safety evaluations such as vital signs, laboratory tests, electrocardiograms, and suicidality ratings. Researchers will also monitor withdrawal symptoms and sexual functioning during the open-label phase. The total participation duration may extend over several months to evaluate both efficacy and long-term safety outcomes.